Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab23981 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ICC/IF Use at an assay dependent concentration.
IHC-P Use at an assay dependent dilution. PubMed: 19092814
WB Use a concentration of 1 µg/ml. Detects a band of approximately 60 kDa (predicted molecular weight: 57 kDa).Can be blocked with Human RUNX2 peptide (ab26346).
Gel supershift assays Use at an assay dependent dilution.

Target

  • FunctionTranscription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificitySpecifically expressed in osteoblasts.
  • Involvement in diseaseDefects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
  • Sequence similaritiesContains 1 Runt domain.
  • DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
  • Post-translational
    modifications
    Phosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
  • Cellular localizationNucleus.
  • Target information above from: UniProt accession Q13950 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • Acute myeloid leukemia 3 protein antibody
    • alpha subunit 1 antibody
    • AML3 antibody
    • CBF alpha 1 antibody
    • CBF-alpha-1 antibody
    • CBFA1 antibody
    • CCD antibody
    • CCD1 antibody
    • cleidocranial dysplasia 1 antibody
    • Core binding factor antibody
    • Core binding factor runt domain alpha subunit 1 antibody
    • Core binding factor subunit alpha 1 antibody
    • core-binding factor antibody
    • Core-binding factor subunit alpha-1 antibody
    • MGC120022 antibody
    • MGC120023 antibody
    • Oncogene AML 3 antibody
    • Oncogene AML-3 antibody
    • OSF 2 antibody
    • OSF-2 antibody
    • OSF2 antibody
    • Osteoblast specific transcription factor 2 antibody
    • Osteoblast-specific transcription factor 2 antibody
    • OTTHUMP00000016533 antibody
    • PEA2 alpha A antibody
    • PEA2-alpha A antibody
    • PEA2aA antibody
    • PEBP2 alpha A antibody
    • PEBP2-alpha A antibody
    • PEBP2A1 antibody
    • PEBP2A2 antibody
    • PEBP2aA antibody
    • PEBP2aA antibody
    • PEBP2aA1 antibody
    • Polyomavirus enhancer binding protein 2 alpha A subunit antibody
    • Polyomavirus enhancer-binding protein 2 alpha A subunit antibody
    • runt domain antibody
    • Runt related transcription factor 2 antibody
    • runt-related transcription factor 2 antibody
    • RUNX2 antibody
    • RUNX2_HUMAN antibody
    • SL3 3 enhancer factor 1 alpha A subunit antibody
    • SL3-3 enhancer factor 1 alpha A subunit antibody
    • SL3/AKV core binding factor alpha A subunit antibody
    • SL3/AKV core-binding factor alpha A subunit antibody
    see all

Anti-RUNX2 antibody images

  • Anti-RUNX2 antibody (ab23981) at 1 µg/ml + Saos 2 (Human epithelial-like osteosarcoma cell line) Nuclear Extract at 20 µg

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 57 kDa


    Exposure time : 8 minutes
  • ab23981 at a 1/1000 dilution staining RUNX2 in human U2-OS cells by Immunocytochemistry/ Immunofluorescence.
    Cells were fixed in paraformaldehyde and permeabilized using 0.1% Triton X-100. Samples were blocked using 2% serum. The secondary used was an Alexa Fluor® 488 conjugated chicken anti-mouse at a 1/1000 dilution.

References for Anti-RUNX2 antibody (ab23981)

This product has been referenced in:
  • Bertazzo S  et al. Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat Mater 12:576-83 (2013). Read more (PubMed: 23603848) »
  • Tang N  et al. Up-regulated osteogenic transcription factors during early response of human periodontal ligament stem cells to cyclic tensile strain. Arch Med Sci 8:422-30 (2012). WB ; Human . Read more (PubMed: 22851995) »

See all 8 Publications for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (U2OS)
Specification U2OS
Fixative Formaldehyde
Permeabilization Yes - NP40
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 21°C
Username

Abcam user community

Verified customer

Submitted Oct 08 2012

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products.

I am sorry these products did not perform as stated on the datasheet and for the inconvenience th...

Read More

Thank you for your inquiry.

We have a number of antibodies in our catalog that might be of interest to you. The following RUNX2 antibodies are tested and therefore covered by our 6 month guarantee in both paraffin embedded sections and mouse...

Read More
Application Immunocytochemistry
Sample Human Cultured Cells (primary smooth muscle cells)
Specification primary smooth muscle cells
Fixative Methanol
Permeabilization Yes - 0.5% NP40/PBS
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Mar 21 2012

Application Western blot
Sample Dog Cell lysate - whole cell (Bone derived osteoblasts)
Loading amount 50 µg
Specification Bone derived osteoblasts
Gel Running Conditions Reduced Denaturing (10%)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Dr. Ali Mobasheri

Verified customer

Submitted Feb 04 2011

Abreviews
Application ChIP
Sample Human Cell lysate - whole cell (Mesenchymal stem cell)
Specification Mesenchymal stem cell
Type Cross-linking (X-ChIP)
Duration of cross-linking step: 8 minute(s) and 0 second(s)
Specification of the cross-linking agent: 1% formaldehyde
Detection step Real-time PCR
Positive control PCR on ChIP DNA with primers against anticipated RUNX2 target sequences containing OSE2 elements: RUNX2 promoter, BGLAP promoter
Negative control PCR with primers against sequences that do not contain OSE2 elements: GAPDH promoter, Satellite 2 sequence

No antibody control
Username

Abcam user community

Verified customer

Submitted Nov 26 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (U2-OS)
Specification U2-OS
Fixative Paraformaldehyde
Permeabilization Yes - 0.1% Triton-X-100/PBS
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Jul 25 2008

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"